Shilpa Medicare Ltd
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics.[1]
- Market Cap ₹ 8,815 Cr.
- Current Price ₹ 901
- High / Low ₹ 960 / 418
- Stock P/E 92.3
- Book Value ₹ 276
- Dividend Yield 0.00 %
- ROCE 6.26 %
- ROE 3.94 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Stock is trading at 3.26 times its book value
- The company has delivered a poor sales growth of -9.95% over past five years.
- Company has a low return on equity of 3.05% over last 3 years.
- Dividend payout has been low at 4.67% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -5.79%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
527 | 565 | 676 | 734 | 741 | 664 | 806 | 257 | 357 | 248 | 310 | 477 | |
410 | 429 | 511 | 551 | 562 | 487 | 561 | 223 | 335 | 291 | 284 | 353 | |
Operating Profit | 118 | 137 | 164 | 183 | 179 | 177 | 245 | 34 | 22 | -44 | 26 | 125 |
OPM % | 22% | 24% | 24% | 25% | 24% | 27% | 30% | 13% | 6% | -18% | 8% | 26% |
9 | 5 | 9 | 15 | 23 | 21 | 32 | 204 | 170 | 159 | 79 | 38 | |
Interest | 3 | 4 | 3 | 3 | 2 | 3 | 4 | 6 | 9 | 21 | 17 | 7 |
Depreciation | 21 | 19 | 21 | 27 | 33 | 34 | 35 | 22 | 35 | 47 | 50 | 49 |
Profit before tax | 102 | 119 | 149 | 169 | 167 | 162 | 238 | 210 | 148 | 48 | 38 | 107 |
Tax % | 21% | 29% | 24% | 24% | 20% | 23% | 19% | 12% | 5% | -18% | 29% | 35% |
81 | 84 | 113 | 127 | 133 | 124 | 194 | 184 | 141 | 57 | 27 | 70 | |
EPS in Rs | 10.99 | 10.91 | 14.64 | 15.91 | 16.34 | 15.22 | 23.76 | 22.62 | 16.24 | 6.59 | 3.10 | 7.14 |
Dividend Payout % | 5% | 5% | 4% | 4% | 4% | 7% | 5% | 5% | 7% | 0% | 0% | 14% |
Compounded Sales Growth | |
---|---|
10 Years: | -2% |
5 Years: | -10% |
3 Years: | 10% |
TTM: | 54% |
Compounded Profit Growth | |
---|---|
10 Years: | 1% |
5 Years: | -14% |
3 Years: | -10% |
TTM: | 182% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 18% |
3 Years: | 27% |
1 Year: | 86% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 5% |
3 Years: | 3% |
Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 |
Reserves | 405 | 555 | 657 | 1,022 | 1,149 | 1,273 | 1,445 | 1,630 | 2,057 | 2,109 | 2,134 | 2,691 |
80 | 87 | 86 | 237 | 186 | 186 | 380 | 655 | 195 | 290 | 144 | 108 | |
134 | 132 | 178 | 224 | 204 | 201 | 188 | 225 | 635 | 112 | 132 | 198 | |
Total Liabilities | 627 | 783 | 929 | 1,490 | 1,547 | 1,668 | 2,021 | 2,517 | 2,896 | 2,519 | 2,419 | 3,007 |
258 | 280 | 350 | 449 | 489 | 511 | 517 | 641 | 566 | 609 | 586 | 812 | |
CWIP | 49 | 88 | 89 | 137 | 201 | 401 | 373 | 482 | 293 | 226 | 228 | 39 |
Investments | 75 | 140 | 154 | 326 | 231 | 89 | 93 | 219 | 238 | 244 | 246 | 1,280 |
245 | 275 | 336 | 579 | 627 | 667 | 1,038 | 1,175 | 1,800 | 1,439 | 1,358 | 876 | |
Total Assets | 627 | 783 | 929 | 1,490 | 1,547 | 1,668 | 2,021 | 2,517 | 2,896 | 2,519 | 2,419 | 3,007 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
59 | 67 | 120 | 50 | 54 | 164 | 130 | 70 | 174 | 2 | 8 | -19 | |
-38 | -139 | -101 | -275 | -13 | -215 | -295 | -238 | -379 | -95 | 156 | -433 | |
-31 | 74 | -15 | 315 | -61 | 8 | 170 | 256 | 97 | 88 | -163 | 450 | |
Net Cash Flow | -10 | 2 | 4 | 91 | -20 | -42 | 5 | 87 | -108 | -5 | 1 | -2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 42 | 45 | 60 | 83 | 107 | 100 | 103 | 310 | 105 | 165 | 170 | 146 |
Inventory Days | 130 | 142 | 126 | 173 | 174 | 275 | 283 | 1,847 | 472 | 420 | 458 | 450 |
Days Payable | 103 | 77 | 99 | 103 | 103 | 111 | 105 | 351 | 111 | 142 | 215 | 67 |
Cash Conversion Cycle | 68 | 110 | 87 | 153 | 179 | 264 | 281 | 1,806 | 466 | 443 | 412 | 528 |
Working Capital Days | 60 | 70 | 71 | 127 | 149 | 153 | 306 | 739 | 210 | 816 | 323 | 251 |
ROCE % | 22% | 21% | 21% | 16% | 12% | 11% | 15% | 2% | 1% | -1% | 3% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
16h - Q4 FY25 earnings call: revenue growth, new product launches, regulatory updates, and strategic partnerships.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Annual Secretarial Compliance Report confirming full SEBI regulation compliance for FY 2024-25.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
26 May - Q4/FY2025 conference call audio recording uploaded on company website.
-
Integrated Filing (Financial)
26 May - Shilpa Medicare reports FY25 audited results, Rs.1 dividend, legal settlement of Rs.29.1 Cr with Celltrion, and auditor appointments.
-
Board Meeting Outcome Financial Results For The Quarter And Year Ended 31 March 2025
26 May - Shilpa Medicare reports FY25 audited results, Rs.1 dividend, auditor appointments, and legal settlement provisions.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Feb 2025TranscriptNotesPPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jul 2024TranscriptPPT
-
May 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT REC
-
Feb 2023Transcript PPT REC
-
Nov 2022TranscriptPPT
-
Nov 2022Transcript PPT REC
-
Aug 2022Transcript PPT REC
-
Feb 2022TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
Established Business of API & Formulations
The Co. is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. [1] The API facilities are approved by several national and international regulatory bodies like USFDA, EU, Cofepris- Mexico, PMDA-Japan, Korean FDA, TPD Canada & TGA-Australia. [2]
It has about 19 API & intermediate manufacturing blocks with segregation of Oncology and Non-Oncology manufacturing facilities. [3]
It has vertically integrated the formulations segment. It manufactures Injectable Dosage Forms, Oral Solid Dosage Forms, Oral Disintegrating Films, and various prescription and OTX products for the overseas and Indian markets. [4]